The synthetic bryostatin analog Merle 23 dissects distinct mechanisms of bryostatin activity in the LNCaP human prostate cancer cell line

Noemi Kedei, Andrea Telek, Alexandra Czap, Emanuel S. Lubart, Gabriella Czifra, Dazhi Yang, Jinqiu Chen, Tyler Morrison, Paul K. Goldsmith, Langston Lim, Poonam Mannan, Susan H. Garfield, Matthew B. Kraft, Wei Li, Gary E. Keck, Peter M. Blumberg

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Bryostatin 1 has attracted considerable attention both as a cancer chemotherapeutic agent and for its unique activity. Although it functions, like phorbol esters, as a potent protein kinase C (PKC) activator, it paradoxically antagonizes many phorbol ester responses in cells. Because of its complex structure, little is known of its structure-function relations. Merle 23 is a synthetic derivative, differing from bryostatin 1 at only four positions. However, in U-937 human leukemia cells, Merle 23 behaves like a phorbol ester and not like bryostatin 1. Here, we characterize the behavior of Merle 23 in the human prostate cancer cell line LNCaP. In this system, bryostatin 1 and phorbol ester have contrasting activities, with the phorbol ester but not bryostatin 1 blocking cell proliferation or tumor necrosis factor alpha secretion, among other responses. We show that Merle 23 displays a highly complex pattern of activity in this system. Depending on the specific biological response or mechanistic change, it was bryostatin-like, phorbol ester-like, intermediate in its behavior, or more effective than either. The pattern of response, moreover, varied depending on the conditions. We conclude that the newly emerging bryostatin derivatives such as Merle 23 provide powerful tools to dissect subsets of bryostatin mechanism and response.

Original languageEnglish
Pages (from-to)1296-1308
Number of pages13
JournalBiochemical Pharmacology
Volume81
Issue number11
DOIs
Publication statusPublished - Jun 1 2011

    Fingerprint

Keywords

  • Bryostatin analog
  • Cell signaling
  • Phorbol ester
  • Protein kinase C

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Cite this

Kedei, N., Telek, A., Czap, A., Lubart, E. S., Czifra, G., Yang, D., Chen, J., Morrison, T., Goldsmith, P. K., Lim, L., Mannan, P., Garfield, S. H., Kraft, M. B., Li, W., Keck, G. E., & Blumberg, P. M. (2011). The synthetic bryostatin analog Merle 23 dissects distinct mechanisms of bryostatin activity in the LNCaP human prostate cancer cell line. Biochemical Pharmacology, 81(11), 1296-1308. https://doi.org/10.1016/j.bcp.2011.03.018